A chemist who runs a two-person biotech with a billion-dollar resume and one very specific idea about how to kill a tumor.
David N. Cook does not run the kind of biotech that fills a glass tower with white coats. Edgewood Oncology, the company he founded and leads as CEO, lists a headcount you could seat at a small dinner table. There is no sprawling lab, no factory floor, no army of bench scientists on the payroll. There is a strategy, a syndicate of investors, and a single drug candidate called BTX-A51 that Cook believes can do something most cancer drugs cannot.
The pitch is unusually concrete. Most therapies attack a tumor from the outside, poisoning fast-dividing cells and hoping the patient holds up better than the disease. BTX-A51 takes a different route. It is a first-in-class small molecule, a multi-kinase inhibitor that simultaneously co-targets three of the master regulators a cancer cell leans on to keep itself alive. Block all three, the thesis goes, and the cell does the rest of the work itself - it switches on apoptosis, the built-in self-destruct program every cell carries and most cancers have learned to mute.
That is the whole company in one sentence: get one good drug to patients with no good options, and waste nothing on the way there.
Before Edgewood, Cook spent decades inside the machinery of biotech as a CEO and Chief Scientific Officer - at Forma Therapeutics, Seres Therapeutics, Anza Therapeutics, Eligix, and Cerus. The work was the unglamorous, hard part of the industry: raising the money, building the teams, steering programs through clinical development, and engineering the exits. He played a role in two corporate acquisitions and contributed to a late-stage program in sickle cell disease.
In 2020 he was named Chief Scientific Officer at Forma Therapeutics, one stop in a career that kept circling back to the same question - how do you turn promising chemistry into a product that reaches a patient.
The academic spine underneath all of it is pure chemistry. Cook earned an A.B. from Harvard University and a Ph.D. in chemistry from the University of California, Berkeley. He is, first and last, a molecule person who happens to be very good at the boardroom.
Cancer cells survive by keeping a few critical switches jammed in the "on" position. BTX-A51 jams them back. It is a multi-kinase inhibitor that co-targets three master regulators at the same time.
Casein kinase 1 alpha - a regulator cancer cells exploit to dodge their own death signals.
A cyclin-dependent kinase that helps drive the runaway transcription tumors depend on.
The third switch - hitting it alongside the others is meant to be synergistic, not additive.
A Phase 2a combination study pairs BTX-A51 with azacitidine. Preclinical work suggested the drug acts synergistically with both azacitidine and venetoclax.
A targeted breast cancer study aimed at a genetically-defined patient population - precision medicine, not a broad sweep.
In 2025 Edgewood dosed its first patient in a Phase 1 investigator-sponsored study and presented new preclinical data at AACR.
“ A precision medicine approach for patients who lack effective treatment options. — David N. Cook, on the BTX-A51 strategy
BTX-A51 did not start in Cook's hands. Its science traces to the lab of scientific founder Yinon Ben-Neriah at the Hebrew University of Jerusalem. Edgewood licensed the molecule through the university's tech-transfer arm, Yissum, then built a company around it.
Appointed CSO at Forma Therapeutics, one chapter in a long run of leadership roles.
Edgewood acquires rights to BTX-A51 from Yissum at the Hebrew University of Jerusalem.
Edgewood emerges from stealth with a Series A led by Alta Partners.
Phase 1 investigator-sponsored study begins; new preclinical data presented at AACR 2025.
Appointed to the Board of Managers, lending his development experience to another clinical-stage company.
Years building venture-backed life sciences companies.
Corporate acquisitions he helped orchestrate.
Master regulators of cancer that BTX-A51 hits at once.
Degrees in chemistry - Harvard and UC Berkeley.
The investors seem to like the discipline of it. Dan Janney of Alta Partners, who sits on Edgewood's board alongside Cook and Isan Chen, framed the appeal plainly: a virtual approach to drug development is the way to get innovative medicines to patients quickly and efficiently. Chief Medical Officer Zung Thai pointed to the early signal - complete responses and a wide therapeutic window in the clinic, synergy in the lab.
None of that is a guarantee. Drugs fail in the clinic for reasons that look obvious only in hindsight, and a three-target mechanism is an ambitious thing to get exactly right. But the shape of Cook's bet is clear and it is consistent with everything that came before it: find the strongest available science, strip the company down to what the science actually needs, and point all of it at patients who have run out of choices.
For a man who has already taken companies public and watched them get acquired, the interesting move was to start over small. Edgewood is the argument that, sometimes, that is the fastest way to do something that matters.